



## Summary of the Risk Management Plan (RMP) for Cerdelga®

Cerdelga® (eliglustat)

Marketing Authorisation Holder : Sanofi-Aventis (Suisse) SA

EU-RMP version 7.1

Date: 17 Nov. 2023

### **Disclaimer:**

The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimise them.

The RMP summary of Cerdelga® is a concise document and does not claim to be exhaustive. As the RMP is an international document, the summary might differ from the "Arzneimittelinformation/Information sur le médicament" approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorisation.

Please note that the reference document which is valid and relevant for the effective and safe use of Cerdelga® in Switzerland is the "Arzneimittelinformation/ Information sur le médicament" (see [www.swissmedicinfo.ch](http://www.swissmedicinfo.ch)) approved and authorised by Swissmedic. Sanofi-Aventis (Suisse) SA is fully responsible for the accuracy and correctness of the content of this published summary RMP of Cerdelga®.

## I. THE MEDICINE AND WHAT IT IS USED FOR

CERDELGA is authorized for the long-term treatment of adult patients with Gaucher disease type 1 (GD1). The target population is patients who are Cytochrome P4502D6 poor metabolizers (PMs), intermediate metabolizers (IMs) or extensive metabolizers (EMs) (see SmPC for the full indication). It contains eliglustat as the active substance and it is given by oral route of administration.

Further information about the evaluation of CERDELGA's benefits can be found in CERDELGA's EPAR, including in its plain-language summary, available on the European Medicines Agency (EMA) website, under the medicine's webpage:

[https://www.ema.europa.eu/en/documents/overview/cerdelga-epar-medicine-overview\\_en.pdf](https://www.ema.europa.eu/en/documents/overview/cerdelga-epar-medicine-overview_en.pdf)

## II. RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMIZE OR FURTHER CHARACTERIZE THE RISKS

Important risks of CERDELGA, together with measures to minimize such risks and the proposed studies for learning more about CERDELGA's risks, are outlined in the next sections.

Measures to minimize the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and HCPs;
- Important advice on the medicine's packaging;
- The authorized pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (eg, with or without prescription) can help to minimize its risks.

Together, these measures constitute routine risk minimization measures.

In the case of CERDELGA, these measures are supplemented with additional risk minimization measures mentioned under relevant important risks, outlined in the next sections.

In addition to these measures, information about adverse reactions is collected continuously and regularly analyzed, including periodic safety update report (PSUR) assessment so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of CERDELGA is not yet available, it is listed under "missing information" outlined in the next section.

### II.A List of important risks and missing information

Important risks of CERDELGA are risks that need special risk management activities to further investigate or minimize the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of CERDELGA. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (eg, on the long-term use of the medicine);

**Table 36 - List of important risks and missing information**

<b>Important identified risk</b>	None
<b>Important potential risks</b>	Drug-drug interactions - Use with CYP2D6 and/or CYP3A inhibitors - Use with strong CYP3A inducers - Use with P-glycoprotein (P-gp) or CYP2D6 substrates Use of eliglustat in patients who are CYP2D6 indeterminate metabolizers or non-genotyped patients Cardiac conduction disorders and arrhythmias
<b>Missing information</b>	Use in patients with a history of or current cardiac ischemia or heart failure, clinically significant arrhythmias or conduction findings Use during pregnancy and lactation Safety in long-term treatment use Use in patients who are CYP2D6 ultra-rapid metabolizers (URMs)

CYP: Cytochrome P450; P-gp: P-Glycoprotein; URM: Ultra-Rapid Metabolizer.

## II.B Summary of important risks

**Table 37 - Important risks with corresponding risk minimization activities and additional pharmacovigilance activities: Drug-drug interactions - Use with CYP2D6 and/or CYP3A inhibitors - Use with strong CYP3A inducers - Use with P-glycoprotein (P-gp) or CYP2D6 substrates**

<b>Important potential risk: Drug-drug interactions - Use with CYP2D6 and/or CYP3A inhibitors - Use with strong CYP3A inducers - Use with P-glycoprotein (P-gp) or CYP2D6 substrates</b>	
<b>Evidence for linking the risk to the medicine</b>	Drug-drug interaction studies were conducted in healthy volunteers to investigate potential interactions between eliglustat and other drugs that are CYP2D6 or CYP3A inhibitors, CYP3A inducers, or P-gp or CYP2D6 substrates. Additionally, PBPK simulations were performed to evaluate Genz-99067 exposure under various scenarios of co-administration with interacting drug. <b>For strong/moderate/weak CYP2D6 inhibitors:</b> GZGD02007; SIM0106; SIM0319 <b>For strong/moderate/weak CYP3A inhibitors:</b> GZGD01807; SIM0106; SIM0170 and SIM0183, SIM0319 <b>Use of strong/moderate CYP2D6 inhibitor and strong/moderate CYP3A inhibitor:</b> SIM0105; SIM0106 <b>For Strong CYP3A inducer:</b> GZGD02407 <b>For P-gp inhibition:</b> GZGD03610 <b>For CYP2D6 inhibition:</b> GZGD04112; SIM0105
<b>Risk factors and risk groups.</b>	<ul style="list-style-type: none"> <li>• Patients with hepatic impairment.</li> <li>• Consumption of grapefruit products (CYP3A inhibitors).</li> </ul>
<b>Risk minimization measures</b>	<b>Routine risk minimization measures:</b> <ul style="list-style-type: none"> <li>• Labeled in sections 4.2, 4.3, 4.4, 4.5 and 5.2 of SmPC.</li> <li>• Labeled in sections 2 and 3 of PIL.</li> </ul> <b>Additional risk minimization measures:</b> <ul style="list-style-type: none"> <li>• Guide for Prescriber.</li> <li>• Patient Alert Card.</li> </ul>
<b>Additional pharmacovigilance activities</b>	Drug utilization study in Europe (ELIGLC06913).

CYP: Cytochrome P450; PBPK: Physiologically Based Pharmacokinetic; P-gp: P-Glycoprotein; SmPC: Summary of Product Characteristics

**Table 38 - Important risks with corresponding risk minimization activities and additional Pharmacovigilance activities: Use of eliglustat in patients who are CYP2D6 indeterminate metabolizers or non-genotyped patients**

<b>Important potential risk: Use of eliglustat in patients who are CYP2D6 indeterminate metabolizers or non-genotyped patients</b>	
<b>Evidence for linking the risk to the medicine</b>	POH0373, SIM0105, SIM0183, and clinical studies.
<b>Risk factors and risk groups.</b>	Not applicable
<b>Risk minimization measures</b>	<b>Routine risk minimization measures:</b> <ul style="list-style-type: none"> <li>Labeled in sections 4.1, 4.2 and 5.2 of SmPC.</li> </ul>
	<ul style="list-style-type: none"> <li>Labeled in sections 2 and 3 of PIL.</li> <li>Before initiation of treatment with CERDELGA, patients should be genotyped for CYP2D6 to determine the CYP2D6 metabolizer status.</li> </ul> <b>Additional risk minimization measures:</b> Guide for Prescriber
<b>Additional pharmacovigilance activities</b>	Prospective ICGG safety sub-registry (OBS14099).

CYP: Cytochrome P450; ICGG: International Collaborative Gaucher Group; SmPC: Summary of Product Characteristics.

**Table 39 - Important risks with corresponding risk minimization activities:  
Cardiac conduction disorders and arrhythmias**

<b>Important potential risk: Cardiac conduction disorders and arrhythmias</b>	
<b>Evidence for linking the risk to the medicine</b>	ISS; ISS ECG Report; GZGD00304, GZGD02507; GZGD02607; GZGD03109; Aggregate AE Report.
<b>Risk factors and risk groups.</b>	<p><u>Cardiac conduction disorders</u></p> <p>Patients with a prior history of conduction disease are more likely to experience blocks. There is an increased risk of first-degree block with increased age as well as some medical conditions (eg, ischemic heart disease, congenital heart disease, drugs, alcohol use, thyroid disease). Mobitz 1 second degree AV block can occur in normal subjects, athletes, older adults, and in patients with certain heart diseases or who are taking drugs that block the AV node (eg, digoxin, beta blockers, calcium channel blockers).</p> <p><u>Ventricular arrhythmia</u></p> <p>Patients with compromised heart function such as cardiomyopathy, heart failure and ischemia are at increased risk for ventricular arrhythmia. Coronary heart disease was identified as the underlying cause of 62% of sudden cardiac deaths. Higher rates of sudden cardiac death were associated with increased age and male gender. (67)</p> <p>Patients with congenital long QT syndrome are at greater risk for a long QTc interval. The use of medications that are known torsadogens or potential torsadogens are also known to increase the QTc interval, which may put a patient at increased risk of Torsade de Pointes. The effect of taking multiple drugs may be additive.</p> <p><u>Use of concomitant CYP2D6 and CYP3A inhibitors</u></p> <p>Extensive metabolizers and IMs using concomitant strong or moderate CYP2D6 inhibitors together with strong or moderate CYP3A inhibitors, and PMs using a strong CYP3A inhibitor are at increased risk to achieve substantially elevated eliglustat exposure which could potentially lead to increases in ECG intervals.</p> <p><u>Hepatic impairment</u></p> <p>Since metabolism is the predominant route of elimination, CYP2D6 IM and PM patients with any degree of HI and CYP2D6 EM patients with moderate and severe HI, as well as CYP2D6 EM patients with mild HI using a strong or moderate CYP2D6 inhibitor, are at increased risk to achieve substantially elevated eliglustat exposure which could potentially lead to increases in ECG intervals.</p>
<b>Risk minimization measures</b>	<p><b>Routine risk minimization measures:</b></p> <ul style="list-style-type: none"> <li>• Labeled in sections 4.3, 4.4 and 4.5 of SmPC.</li> <li>• Labeled in section 2 of PIL.</li> </ul> <p><b>Additional risk minimization measures:</b></p> <p>None</p>

AE: Adverse Event; AV: Atrioventricular; CYP: Cytochrome P450; ECG: Electrocardiogram; EM: Extensive Metabolizer; HI: Hepatic Impairment; IM: Intermediate Metabolizer; ISS: Integrated Safety Summary; PM: Poor Metabolizer; PIL: Patient Information Leaflet; SmPC: Summary of Product Characteristics.

**Table 40 - Missing information with corresponding risk minimization activities: Use in patients with a history of or current cardiac ischemia or heart failure, clinically significant arrhythmias or conduction findings**

<b>Missing Information: Use in patients with a history of or current cardiac ischemia or heart failure, clinically significant arrhythmias or conduction findings</b>	
<b>Risk minimization measures</b>	<b>Routine risk minimization measures:</b> <ul style="list-style-type: none"> <li>• Labeled in section 4.4 of SmPC.</li> <li>• Labeled in section 2 of PIL.</li> </ul> <b>Additional risk minimization measures:</b> None

PIL: Patient Information Leaflet; SmPC: Summary of Product Characteristics.

**Table 41 – Missing information with corresponding risk minimization activities: Use during pregnancy and lactation**

<b>Missing information: Use during pregnancy and lactation</b>	
<b>Risk minimization measures</b>	<b>Routine risk minimization measures:</b> <ul style="list-style-type: none"> <li>• Labeled in section 4.6 of SmPC.</li> <li>• Labeled in section 2 of PIL.</li> </ul> <b>Additional risk minimization measures:</b> None

PIL: Patient Information Leaflet; SmPC: Summary of Product Characteristics.

**Table 42 – Missing information with corresponding additional pharmacovigilance activities: Safety in long-term treatment use**

<b>Missing information: Safety in long-term treatment use</b>	
<b>Risk minimization measures</b>	<b>Routine risk minimization measures:</b> None <b>Additional risk minimization measures:</b> None
<b>Additional pharmacovigilance activities</b>	Prospective ICGG safety sub-registry (OBS14099).

ICGG: International Collaborative Gaucher Group.

**Table 43 - Missing information with corresponding risk minimization activities additional pharmacovigilance activities: Use in patients who are CYP2D6 ultra-rapid metabolizers (URMs)**

<b>Missing information: Use in patients who are CYP2D6 ultra-rapid metabolizers (URMs)</b>	
<b>Risk minimization measures</b>	<b>Routine risk minimization measures:</b> <ul style="list-style-type: none"> <li>• Labeled in sections 4.2 and 4.4 of SmPC.</li> <li>• Labeled in section 2 of PIL.</li> </ul> <b>Additional risk minimization measures:</b> None
<b>Additional pharmacovigilance activities</b>	Prospective ICGG safety sub registry (OBS14099).

ICGG: International Collaborative Gaucher Group; PIL: Patient Information Leaflet; SmPC: Summary of Product Characteristics; URM: Ultra-Rapid Metabolizer.

## **II.C Post-authorization development plan**

### **II.C.1 Studies which are conditions of the marketing authorization**

The following studies are conditions of the marketing authorization:

**Table 44 - Studies which are conditions of the marketing**

---

**authorization Prospective ICGG safety sub-registry (OBS14099)**

---

Purpose of the study:

A prospective ICGG safety sub registry to characterize the long-term safety profile of eliglustat.  
To describe the patient's characteristics and utilization patterns.

---

ICGG: International Collaborative Gaucher Group.

### **II.C.2 Other studies in post-authorization development plan**

**Table 45 - Other studies in post-authorization development plan**

---

**Drug utilization study of eliglustat in Europe using electronic healthcare records (ELIGLC06913)**

---

Purpose of the study:

To assess compliance/adherence to the labeling with regard to drug-drug interactions.

---

## REFERENCES

1. Cornel MC. Common language for measures of occurrence of congenital anomalies and genetic diseases: incidence or birth prevalence. *Community Genet.* 1999;2(4):162-4.
2. Mason CA, Kirby RS, Sever LE, Langlois PH. Prevalence is the preferred measure of frequency of birth defects. *Birth Defects Res A Clin Mol Teratol.* 2005 Oct;73(10):690-2.
3. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. *JAMA.* 1999 Jan 20;281(3):249-54.
4. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. *Hum Genet.* 1999 Jul-Aug;105(1- 2):151-6.
5. Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. *Eur J Hum Genet.* 2004 Feb;12(2):87-92.
6. Grabowski GA, Horowitz M. Gaucher's disease: molecular, genetic and enzymological aspects. *Baillieres Clin Haematol.* 1997 Dec;10(4):635-56.
7. Orphadata [Internet]. Prevalence of rare diseases: Bibliographic data, Orphanet Report Series, Rare Diseases collection, Number 1 : Listed in alphabetical order of disease or group of diseases. [accessed on 2013 Jun]. Available from: [http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence\\_of\\_rare\\_diseases\\_by\\_alphabetical\\_list.pdf](http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf)
8. Grabowski GA, Petsko GA, Kolodny EH. Gaucher Disease. In: Valle D. et al, eds. *The Online Metabolic and Molecular Bases of Inherited Disease.* New York, NY: McGraw-Hill; 2010: Chapter 146.
9. Zimran A, Gelbart T, Westwood B, Grabowski GA, Beutler E. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. *Am J Hum Genet.* 1991 Oct;49(4):855-9.
10. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. *Arch Intern Med.* 2000 Oct 9;160(18):2835-43.
11. Dionisi-Vici C, Rizzo C, Burlina AB, Caruso U, Sabetta G, Uziel G, et al. Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. *J Pediatr.* 2002 Mar;140(3):321-7.
12. Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. *Oncologist* 2006 ;11(2):126-35.
13. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. *Fundam Clin Pharmacol.* 2007 Aug;21(4):419-26.
14. Correia C, Santos P, Coutinho AM, Vicente AM. Characterization of pharmacogenetically relevant CYP2D6 and ABCB1 gene polymorphisms in a Portuguese population sample. *Cell Biochem Funct.* 2009 Jun;27(4):251-5.
15. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics J.* 2005;5(1):6-13.

16. Menoyo A, del Rio E, Baiget M. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. *Cell Biochem Funct.* 2006 Sep-Oct;24(5):381-5.
17. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. *Pharmacol Res.* 2004 Aug;50(2):195- 200.
18. Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. *Croat Med J.* 2003 Aug;44(4):425-8.
19. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. *Am J Hum Genet.* 1997 Feb;60(2):284-95.
20. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. *Br J Clin Pharmacol.* 2002 Feb;53(2):111-22.
21. Rideg O, Haber A, Botz L, Szucs F, Varnai R, Miseta A, et al. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population. *Cell Biochem Funct.* 2011 Oct;29(7):562-8.
22. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). *Hum Mutat.* 2008 May;29(5):567- 83.
23. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. *Am J Med.* 2002 Aug 1;113(2):112-9.
24. Weinreb NJ, Deegan P, Kacena KA, Mistry P, Pastores GM, Velentgas P, et al. Life expectancy in Gaucher disease type 1. *Am J Hematol.* 2008 ec;83(12):896-900.
25. Hill SC, Reinig JW, Barranger JA, Fink J, Shawker TH. Gaucher disease: sonographic appearance of the spleen. *Radiology.* 1986 Sep;160(3):631-4.
26. Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, et al. The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients. *Orphanet J Rare Dis.* 2012 Oct 9;7:77.
27. Zimran A, Elstein D, Schiffmann R, Abrahamov A, Goldberg M, Bar-Maor JA, et al. Outcome of partial splenectomy for type I Gaucher disease. *J Pediatr* 1995 Apr;126(4):596-7.
28. Ayto RM, Hughes DA, Jeevaratnam P, Rolles K, Burroughs AK, Mistry PK, et al. Long-term outcomes of liver transplantation in type 1 Gaucher disease. *Am J Transplant.* 2010 Aug;10(8):1934-9.
29. Vom Dahl S, Poll L, Di Rocco M, Ciana G, Denes C, Mariani G, et al. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. *Curr Med Res Opin.* 2006 Jun;22(6):1045-64.
30. Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuropathic Gaucher disease in 887 children at diagnosis. *Arch Pediatr Adolesc Med.* 2006 Jun;160(6):603-8.

31. Khan A, Hangartner T, Weinreb NJ, Taylor JS, Mistry PK. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. *J Bone Miner Res.* 2012 Aug;27(8):1839-48.
32. Parisi MS, Mastaglia SR, Bagur A, Goldstein G, Zeni SN, Oliveri B. Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase. *Eur J Med Res.* 2008 Jan 23;13(1):31-8.
33. Mikosch P, Reed M, Stettner H, Baker R, Mehta AB, Hughes DA. Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry. *Mol Genet Metab.* 2009 Mar;96(3):113-20.
34. Mikosch P, Hughes D. An overview on bone manifestations in Gaucher disease. *Wien Med Wochenschr.* 2010 Dec;160(23-24):609-24.
35. Michaelsson K, Nordstrom P, Nordstrom A, Garmo H, Byberg L, Pedersen NL, et al. Impact of hip fracture on mortality: a cohort study in hip fracture discordant identical twins. *J Bone Miner Res.* 2014 Feb;29(2):424-31.
36. Hughes D, Cappellini MD, Berger M, Van Droogenbroeck J, de Fost M, Janic D et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. *Br J Haematol.* 2007 Sep;138(6):676-86. Epub 2007 Jul 26.
37. Weinreb NJ, Lee RE. Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy. *Crit Rev Oncog.* 2013;18(3):177-95.
38. Landgren O, Turesson I, Gridley G, Caporaso NE. Risk of malignant disease among 1525 adult male US Veterans with Gaucher disease. *Arch Intern Med.* 2007 Jun 11;167(11):1189-94.
39. de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. *Blood Cells Mol Dis.* 2006 Jan- Feb;36(1):53-8.
40. de Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH, et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. *Ann Hematol.* 2008 Jun;87(6):439-49.
41. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. *Br J Haematol.* 2007 Dec;139(5):730-43.
42. Halperin A, Elstein D, Zimran A. Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease? *Acta Neurol Scand.* 2007 Apr;115(4):275-8.
43. Capablo JL, Saenz de Cabezón A, Fraile J, Alfonso P, Pocovi M, Giraldo P; Spanish Group on Gaucher Disease. Neurological evaluation of patients with Gaucher disease diagnosed as type 1. *J Neurol Neurosurg Psychiatry.* 2008 Feb;79(2):219-22.
44. Cherin P, Rose C, de Roux-Serratrice C, Tardy D, Dobbelaere D, Grosbois B, et al. The neurological manifestations of gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). *J Inherit Metab Dis.* 2010 Aug;33(4):331-8.
45. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE. 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. *J Inherit Metab Dis.* 2008 Jun;31(3):337-49.

46. Biegstraaten M, Mengel E, Marodi L, Petakov M, Niederau C, Giraldo P, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. *Brain*. 2010 Oct;133(10):2909-19.
47. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. *Arch Neurol*. 2008 Oct;65(10):1353-7.
48. Rosenbloom B, Balwani M, Bronstein JM, Kolodny E, Sathe S, Gwosdow AR, et al. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. *Blood Cells Mol Dis*. 2011 Jan 15;46(1):95-102.
49. Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, et al. The risk of Parkinson's disease in type 1 Gaucher disease. *J Inherit Metab Dis*. 2010 Apr;33(2):167-73.
50. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. *Mol Genet Metab*. 2004 Jan;81(1):70-3.
51. Chahine LM, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. *JAMA Neurol*. 2013 Jul;70(7):852-8.